Back to Search
Start Over
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
- Source :
-
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 1990; Vol. 25 (4), pp. 263-6. - Publication Year :
- 1990
-
Abstract
- A total of 42 patients with cerebral metastases of malignant melanoma were included in this study of the nitrosourea fotemustine. The treatment plan consisted of a l-h i.v. infusion of 100 mg/m2 fotemustine every week for 3-4 weeks, followed by a 4- to 5-week rest period. Responding or stabilised patients then received 100 mg/m2 fotemustine every 3 weeks. Among the 39 evaluable patients, 2 complete responses and 9 partial responses were documented, leading to an overall response rate of 28.2%. Most of the responses were obtained in previously untreated patients and/or those presenting with a single cerebral metastasis. Toxicity was mild and mainly hematological, especially in patients previously treated by polychemotherapeutic regimen. Our study confirms the activity of fotemustine in cerebral metastases of disseminated malignant melanoma.
- Subjects :
- Adult
Aged
Antineoplastic Agents adverse effects
Brain Neoplasms diagnostic imaging
Brain Neoplasms mortality
Brain Neoplasms secondary
Drug Administration Schedule
Drug Evaluation
Female
Humans
Male
Melanoma diagnostic imaging
Melanoma mortality
Melanoma secondary
Middle Aged
Multicenter Studies as Topic
Nitrosourea Compounds adverse effects
Organophosphorus Compounds adverse effects
Remission Induction
Tomography, X-Ray Computed
Antineoplastic Agents therapeutic use
Brain Neoplasms drug therapy
Melanoma drug therapy
Nitrosourea Compounds therapeutic use
Organophosphorus Compounds therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0344-5704
- Volume :
- 25
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Cancer chemotherapy and pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 2403853
- Full Text :
- https://doi.org/10.1007/BF00684883